Introduction
Borderline ovarian tumors (BOTs) were first described by Taylor (1929) and represent 10-20% of all ovarian epithelial tumors. They are characterized by low-grade malignancy, rarely metastasizing, but showing bilateral disease in 15-40% of patients at diagnosis (Zanetta et al., 2001; Donnez et al., 2003) . BOTs are typically diagnosed at an early stage and thus usually have an excellent prognosis, but in 2-4% of cases, they can evolve into more aggressive lesions, considerably worsening the prognosis of the patient. The mean age at diagnosis is 45 years, but one-third of the patients are under 40 years of age and therefore potential candidates for fertility-sparing surgery (Donnez et al., 2003; Morice, 2006) .
Radical surgery with bilateral salpingo-oophorectomy is the gold standard treatment for BOT patients, but conservative surgery, either unilateral salpingo-oophorectomy or cystectomy, can be performed to preserve fertility in the youngest patients (Fauvet et al., 2005; Morice, 2006) . The risk of recurrence after unilateral salpingo-oophorectomy is higher than after radical surgery (0-25 versus 0-5%) (Donnez et al., 2003; Morice, 2006) , and even higher in case of cystectomy (Daraï et al., 2013; Chen et al., 2016) . Relapses almost always show BOT histology, and they can therefore be safely managed with a second surgical intervention (Uzan et al., 2010) . Although it has been shown that recurrence has no impact on survival (Zanetta et al., 2001; Tropé et al., 2012) , the disease may recur contralaterally on the spared ovary, or involve both ovaries, necessitating a second intervention with radical surgery (Donnez et al., 2003) .
In young patients who have yet to consider future childbearing, fertility preservation is of even greater importance. Spontaneous conception after conservative management is achieved in more than 75% of women (Donnez et al., 2003; Chen et al., 2016) . Ovarian stimulation followed by oocyte or embryo cryopreservation is a good option for patients who do not wish to conceive immediately, with successful results reported in BOT patients (Fortin et al., 2007; Mangili et al., 2016) . Ovarian tissue cryopreservation (OTC) can also be considered (Fain-Kahn et al., 2009; . OTC has proved to be a valuable strategy in prepubertal patients and those who cannot delay anticancer treatment, and its efficacy has increased over the last 10 years, with more than 110 live births reported to date Donnez and Dolmans, 2015; Jensen et al., 2017) .
The aim of this study was therefore to evaluate the presence of BOT cells in ovarian tissue from women with BOTs at the time of cryopreservation and the risk of recurrence after grafting.
Materials and Methods

Marker selection
To evaluate minimal residual disease (MRD) in the cryopreserved ovarian tissue from women with BOTs, immunohistochemistry (IHC), reversetranscribed quantitative polymerase chain reaction (RT-qPCR) and longterm (5 months) xenografting to immunodeficient mice were performed using disease-specific molecular markers. To this end, we first identified a list of possible markers by conducting a meticulous Medline search of the literature from 2004 to 2017 (PubMed) and consulting online data (http:// www.proteinatlas.org/). A number of markers were evaluated and analyzed, considering their sensitivity and specificity to the different histological characteristics of this pathology. The two markers finally selected were mucin 1 (MUC1) (Halimi et al., 2013) and cytokeratin 7 (CK7) (Kim et al., 2010; Halimi et al., 2013) . Both markers have been previously investigated by IHC in serous BOTs and mucinous BOTs, showing 100% expression, therefore, we decided to use these two markers for our study.
Patients
In the period between 1997 and 2017, we performed OTC in 49 patients affected by BOTs in our institution. Frozen-thawed ovarian tissue for the present study was taken from 11 women. Informed consent was obtained from all 11 patients to use their frozen ovarian tissue for research purposes.
The clinical characteristics of patients are shown in Table I . Five patients presented with serous BOTs and six with mucinous BOTs. Nine patients were aged between 25 and 35 years (mean age 29.33 years) when their ovarian tissue was cryopreserved and two were aged 37 and 41 years. In our department, the upper age limit for OTC is now 35, but these two patients presented at the very beginning of our experience before guidelines were in place.
Despite chemotherapy, Patients 5 and 6 died from their disease due to development of malignant ovarian cancer in the former and recurrent peritoneal and lymph node disease in the latter. Patient 1 died in an accident.
Ovarian tissue for cryopreservation was taken from the contralateral normal-looking ovary in 10 of 11 cases. Patient 6 had bilateral disease at diagnosis and ovarian cortex for cryopreservation was retrieved from a macroscopically healthy portion of the ovary. All 11 patients underwent OTC at the time of initial surgery. Five patients later required a second intervention because of contralateral recurrence.
One to two cryovials containing tissue from each patient were thawed and divided into three parts, each measuring~5 × 8 × 1.5 mm 3 , representing a total volume of 180 mm 3 : one for histology and IHC, one for RTqPCR and one for xenografting to mice.
Freezing and thawing procedures
Freezing of ovarian tissue was undertaken according to the slow freezing protocol, as previously described (Gosden et al., 1994; Donnez et al., 2004) . For the thawing procedure, the cryogenic vials were first thawed at room temperature for 2 min and immersed in a water bath at 37°C for another 2 min. Ovarian tissue was then transferred to tissue culture dishes (BD Biosciences, Belgium) in L-15 medium and subsequently washed three times (5 min each) at room temperature with fresh medium to remove cryoprotectant before further processing.
Histology
For each patient, a fragment of frozen-thawed ovarian tissue was fixed in 4% formaldehyde, embedded in paraffin and serially sectioned (5-μm-thick sections). Every third slide was stained with hematoxylin and eosin (Merck, Darmstadt, Germany) for histological evaluation.
Immunohistochemistry
Normal ovarian tissue from healthy patients was used as negative controls and endometrioid ovarian carcinoma and serous BOTs were used as positive controls for MUC1 and CK7 IHC. Mucinous BOTs were not tested as positive controls, since there is adequate evidence in the literature (Kim et al., 2010; Halimi et al., 2013) . MUC1 and CK7 were assessed on their ability to clearly identify neoplastic cells in thawed tissue. Immunohistochemical analysis of MUC1 and CK7 was performed using Ventana's ultraView Universal DAB detection kit on its BenchMark XT module (Roche, Basel, Switzerland). After antigen retrieval by heating histological sections for 20 min, mouse primary antibodies (MUC1, clone E29, Dako, Glostrup, Denmark, 1 μg/ml, dilution 1:80; and CK7, clone OV-TL 12/30, Dako, Glostrup, Denmark, 5 μg/ml, dilution 1:100) were applied for 30 min at room temperature, followed by incubation with the secondary anti-mouse antibody.
In the xenograft from Patient 11, additional analysis with CD10 was performed. CD10 is an immunohistochemical marker of endometrial stroma and its immunoreactivity is maintained in endometrial stromal cells located outside the uterus, proving its value in the diagnosis of endometriosis (Sumathi and Mccluggage, 2002) .
The primary antibody used was mouse anti-CD10 (clone 56C6, Monosan, the Netherlands). Briefly, after inactivation of endogenous peroxidase activity, heat epitope retrieval in citrate buffer (0.01 M) and inhibition of nonspecific staining, tissue specimens were incubated overnight at 4°C with the primary antibody (diluted 1:200). Incubation with anti-mouse secondary antibody conjugated to horseradish peroxidase (Envision+; Dako) was then performed at room temperature for 1 h, followed by peroxidase activity revelation with 3,3′-diaminobenzidine (Dako) and counterstaining with hematoxylin (Merck).
Image acquisition
Slides were analyzed using an Axioskop 50 microscope (Carl Zeiss, Germany) and pictures were taken with a Leica DFC320 (Leica Microsystems Ltd, Germany). Magnifications used are specified in the figure of each micrograph.
RNA isolation and reverse transcription
RNA extraction was performed using the RNeasy Plus mini kit (Qiagen, Germany) according to the manufacturer's recommendations. After thawing, ovarian tissue was placed in 600 μl RLT Plus lysis buffer (+β-mercaptoethanol), and disruption and homogenization were obtained with the TissueRuptor (Janke and Kunkel, Belgium). RNA extraction was then carried out, with RNA quantification achieved using the NanoDrop ND-2000 spectrophotometer (Nanodrop, Wilmington, USA). RNA was immediately stored at −80°C until use. To perform reverse transcription, 1 μg total RNA was denatured at 65°C for 5 min and then placed on ice for 1 min, using 0.5 μl random hexameres (500 ng/μl, Promega #1181, USA) and 3.5 μl dNTP (10 mM Roche, #11969064001, Germany) in a final volume of 14.0 μl. The RNA was subsequently reverse-transcribed for 5 min at room temperature, 1 h at 55°C and 15 min at 70°C, using 0.5 μl SuperScript III (Invitrogen #18080-044, California, USA), 4 μl first strand buffer (5×), 1 μl dithiothreitol (DTT) (0.1 M) and 0.5 μl RNAsin (2500 U, Promega #N2511, USA) in a final volume of 20 μl. cDNA was stored at −20°C.
RT-PCR
Ovarian endometrioid adenocarcinoma and serous BOT biopsies were used as positive controls (n = 5). Ovarian tissue biopsies from patients with benign uterine pathologies were used as negative controls (n = 5).
RT-qPCR was performed on each sample in a final volume of 20 μl, containing 5 μl cDNA, which was amplified using the TaqMan Universal RT-qPCR Master Mix 2× (10 μl, Applied Biosystems USA), two Assays-on-Demand (MUC1: Hs00159357_m1; Applied Biosystems, USA; CK7: Hs00559840_m1; Applied Biosystems, USA) 20× (1 μl) and 4 μl diethyl pyrocarbonate H 2 O. Thermal cycling was carried out with an initial denaturation step at 50°C for 2 min and 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and then 60°C for 1 min (StepOnePlus, Applied Biosystems, USA). Positive and negative controls and ovarian tissue samples were amplified in duplicate and ovarian tissue grafts in simplicate due to the scarcity of material.
Transplantation to severe combined immunodeficient mice
Eleven female severe combined immunodeficient (SCID) mice were used for grafting. They were bred as previously reported (Nisolle et al., 2000) . The animals were given an intraperitoneal injection of medetomidine (1 mg/kg; Domitor, Pfizer, USA) for anesthesia, and buprenorphine (0.1 mg/kg; Temgesic, Schering Plough, USA) for analgesia. A small median laparotomy incision was made in the abdomen and peritoneum, and human ovarian tissue strips were fixed to the inner side of the murine peritoneum with one or two stitches of 6-0 Prolene, as previously described (Dolmans et al., 2010 Prolene and the skin with 4/0 or 3/0 Surgilon. After surgery, anesthesia was reversed by injection of atipamezole (1 mg/kg; Antisedan, Pfizer, USA). The mice were kept in sterile conditions for 5 months, before being euthanized by cervical dislocation. Ovarian grafts were recovered and assigned to RT-qPCR analysis (snap-frozen in liquid nitrogen) and histological evaluation (formaldehyde).
Statistical analysis
Statistical analysis of RT-qPCR results was performed using Graphpad Prism 6.0 for Mac OS. The multiple t-test was applied to compare gene expression between positive and negative controls, and between individual ovarian tissue samples and positive controls. All reported P-values were two-sided and a P-value <0.05 was considered statistically significant. The amount of RNA retrieved from the ovarian tissue xenografts was too small to be amplified in duplicate, so no statistical analyses could be conducted.
Ethical approval
Use of human tissue for this study was approved by the Institutional Review Board of the Université Catholique de Louvain (Registration number B403201213872). Guidelines for animal welfare were fully respected and approval for the study was obtained from the Committee on Animal Research of the Université Catholique de Louvain.
Results
Histology
Results are shown in Table II . At histological analysis of the frozenthawed ovarian tissue, no lesion suspicious for BOT was observed, except in the case of Patient 7, where a glandular lesion composed of columnar epithelial cells with a moderately eosinophilic cytoplasm was observed (Fig. 1a) . Several psammoma bodies were found surrounding the glandular lesion.
Immunohistochemistry
Ten of the 11 frozen-thawed ovarian tissue samples were negative for both MUC1 and CK7 markers. In Patient 7, we performed IHC for MUC1 and CK7 on two slides consecutive to the section investigated at histology (Fig 1a) . Strong membranous staining was detected for both MUC1 and CK7 markers (Fig. 1b and c) .
RT-qPCR analysis
For each sample, the relative amount of RT-qPCR product was determined based on the cycle threshold (Ct) value. Ct values for the GAPDH housekeeping gene (Hs00266705_g1) were determined for normalization purposes, and ΔCt values between CK7 and GAPDH and between MUC1 and GAPDH were calculated. Relative quantification was then performed; results for each gene were expressed as the difference in expression levels between positive control tissue and ovarian tissue samples using the following equation: 2 −ΔΔCt , with
The difference in gene expression of the two markers was evaluated between positive and negative control tissues after normalization with the GAPDH housekeeping gene. CK7 gene expression was significantly higher in positive control tissues than in negative control tissues (P < 0.0001) (Fig. 2) . The MUC1 gene, on the other hand, was found to be expressed in both positive and negative controls (P = 0.4173) (Fig. 2) . As the MUC1 gene did not prove to be a specific marker for BOTs, only CK7 RT-qPCR results were taken into account.
RT-qPCR results are shown in Fig. 3 . CK7 gene expression in each sample was considered positive if levels were above the threshold. In 10 out of 11 frozen-thawed ovarian tissue samples, RT-qPCR results were below the threshold (Fig. 3) , while for Patient 7, it was found to be above the threshold. Statistical significant difference was observed between positive control and each ovarian tissue, with the exception of Patient 7 (P = 0.886). 
NA, not available; ND, not detected; BOT, borderline ovarian tumor; IHC, immunohistochemistry.
Xenografting experiments
Macroscopic analysis
After 5 months of grafting, all 11 mice looked healthy and without visible masses at the transplantation site. Grafted human ovarian tissue was recovered and analyzed. Upon macroscopic evaluation, all the ovarian grafts appeared fibrotic and reduced in size, but follicular activity was observed (Fig. 1d) . Human ovarian tissue grafts were assigned to IHC and RT-qPCR, except in two cases where they were too small and could only be analyzed by RT-qPCR (Patients 2 and 9).
Histology
Histology and IHC could be performed in 9 of the 11 xenografts. Serial sections of the ovarian xenografts were processed for histology. In two cases (Patients 7 and 11), glandular lesions consistent with BOTs were observed at histology (Figs 1e and 4a, Table II ). They were composed of columnar epithelium with an eosinophilic cytoplasm. However, in Patient 7, a number of invaginations were noted and the lesion was found to be surrounded by psammoma bodies (Fig. 1e) . In Patient 11, no invaginations were detected, but a rich stroma was seen surrounding the lesion (Fig. 4a) .
Immunohistochemistry
Diffuse positive staining for both MUC1 and CK7 was also encountered in both cases ( Fig. 1f and g ), but we did not find any suspicious lesions in any of the other patients. Because of the atypical aspect of the lesion in Patient 11, further analysis with CD10 was required to distinguish between a BOT and endometriosis, providing a differential diagnosis. Stroma surrounding the lesion showed strong positive staining for CD10 (Fig. 4b) .
RT-qPCR analysis
RT-qPCR analysis was only possible in 9 of the 11 xenografts because of insufficient RNA in two cases (Patients 5 and 6) ( Table II) . Gene exprexenograft from Patient 7, but below the threshold in all the others (Fig. 3) , including the graft from Patient 11.
Discussion
In this study, by means of IHC for MUC1 and CK7, RT-qPCR for CK7, and long-term xenografting, we detected BOT cells able to survive after transplantation in the cryopreserved ovarian tissue of 1 of 11 patients (9.1%). Safety issues surrounding transplantation of ovarian tissue from cancer patients have been the subject of debate for many years now, and several studies have analyzed the risk of reintroducing malignant cells potentially present in frozen-thawed ovarian tissue that could induce recurrence of the primary tumor . Reimplantation of ovarian tissue from acute leukemia patients has already been deemed unsafe (Dolmans et al., 2010; Rosendahl et al., 2010) . On the other hand, results from studies in breast cancer and bone and soft tissue sarcoma patients are reassuring (Sanchez-Serrano et al., 2009; Luyckx et al., 2013; Dolmans et al., 2016) .
The same issues about safety have also been raised with respect to ovarian tissue reimplantation in BOT patients, as they are also candidates for fertility preservation. The major concern with BOTs is their site of origin, as these tumors arise from the very organ that will later be preserved and reimplanted, increasing the chances of cryopreserving malignant cells together with ovarian tissue. In patients with unilateral disease, biopsies for fertility preservation are taken from the contralateral healthy ovarian cortex during initial surgical procedure, while in case of bilateral disease, the healthiest-looking portion of the least affected ovary is selected for biopsy retrieval. Moreover, BOTs present as bilateral disease in up to 40% of cases already at diagnosis, and recurrences may be observed on the contralateral ovary after initial unilateral adnexectomy (Donnez et al., 2003) , indicating that microscopically occult BOT cells could be present in an ovary originally thought to be healthy.
Many BOT patients have their ovarian tissue frozen and stored in cryobanks but only one study has so far evaluated the safety of transplantation (Lotz et al., 2011) . No malignant cell contamination was found when frozen-thawed ovarian tissue from 10 patients with different types of ovarian tumors was grafted to SCID mice for 24 weeks. It should, however, be noted that the study used only histology and IHC for pan-cytokeratin detection, and more sensitive and specific techniques are required before any decision on reimplantation can be taken.
In our study, 11 ovarian cortical tissue samples from patients affected by BOT were evaluated. Frozen-thawed and grafted ovarian tissue from 9 of 11 patients was negative at histology and IHC for both markers, and at RT-qPCR for CK7.
Patients 7 and 11 were the only two in whom histology revealed the presence of glandular lesions showing signs of BOTs, with IHC evidencing strong staining for both CK7 and MUC1. In Patient 7, molecular analysis detected the CK7 gene both in frozen-thawed ovarian tissue and in the xenograft. Moreover, at histology, the lesion had a micropapillary structure and was surrounded by psammoma bodies, which are typical features of serous BOTs and consistent with the histology of the primary tumor of the patient, confirming the diagnosis of a BOT. Reimplantation of cryopreserved ovarian tissue is not recommended in this case, as there is a risk of reintroducing BOT cells, with the ability to survive, as demonstrated by our xenografting experiments.
In the xenograft from Patient 11, however, the lesion was characterized by different features; no papillary structures nor psammoma bodies were observed, while the stroma surrounding the gland was more apparent and thicker. Since RT-qPCR for CK7 was also negative, we suspected endometriosis, as a differential diagnosis for BOTs. For this reason, we performed IHC with CD10, a well-established and highly specific marker used to diagnose endometriosis. As expected, the stroma surrounding the lesion stained positive for CD10, with strong expression intensity.
Although considered a benign disease, recent studies have reported an association between endometriosis and an increased risk of developing ovarian tumors, both carcinomas and BOTs, (Sayasneh et al., 2011; Buis et al., 2013) . Therefore, when considering ovarian tissue transplantation, caution is vital if endometriotric glands are found in the frozen-thawed ovarian tissue of patients with BOTs. Even though the pathology is benign, there is always the risk of reintroducing cells with the potential to transform into malignant cells. As there is already a risk of reintroducing BOT cells residing within the ovarian tissue itself, careful evaluation of the disease and comprehensive discussion with patients with endometriosis is needed before ovarian tissue transplantation can be contemplated.
In the literature, two pregnancies after transplantation of frozenthawed ovarian tissue in ovarian cancer patients have been reported (Dittrich et al., 2015; Kristensen et al., 2017) . In both cases, the grafted ovarian tissue was removed soon after delivery for safety reasons. The same strategy may be proposed to BOT patients. However, as this approach does not reduce the risk of reintroducing tissue susceptible to BOT or malignancy development, thorough discussion with the patient and preimplantation analysis are essential before obtaining informed consent for the procedure.
Patients 5 and 6 died from their disease due to development of a malignant ovarian carcinoma in one case, and peritoneal and lymph node disease in the other. BOTs are able to recur several years (as many as 10) after primary diagnosis and the disease can present with different features, such as peritoneal invasion and malignant transformation (Daraï et al., 2013) . This could explain the absence of malignant cells at the time of cryopreservation, as it is possible that they may not yet have developed. Moreover, not all ovarian tissue biopsies can be tested prior to transplantation, as preimplantation analysis actually destroys the tissue itself.
In conclusion, in our study, we observed glandular lesions in frozenthawed ovarian tissue and xenografts from two patients; in one case, a BOT was confirmed, and in the other, endometriosis. Histology and IHC were found to be valid techniques for BOT detection after ruling out endometriosis, and RT-qPCR with CK7 showed enough specificity to detect BOT lesions. Although our study reports a small series of patients, we can provide initial insights into the safety of ovarian tissue transplantation in BOT patients and clinical guidance on future indications for the procedure. We can therefore conclude that preimplantation analysis of ovarian cortex must be performed prior to ovarian tissue transplantation, as there is a risk of reintroducing BOT cells able to survive after grafting, even though the risk is relatively low. 
